This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Ovarian Cancer
  • /
  • Rucaparib: A Review in Ovarian Cancer
Journal

Rucaparib: A Review in Ovarian Cancer

Read time: 1 mins
Published:1st Apr 2019
Author: Shirley M.
Availability: Pay for access, or by subscription
Ref.:Target Oncol. 2019;14(2):237-246.
DOI:10.1007/s11523-019-00629-5
Rucaparib: A Review in Ovarian Cancer


Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients with BRCA-mutated ovarian cancer who have been treated with two or more lines of chemotherapy. Rucaparib is also approved in the USA and the EU for use as maintenance therapy in adult patients with recurrent or relapsed ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Based on an analysis of patients across two phase II clinical trials, rucaparib displayed clinical activity as third- (or later-) line treatment of BRCA-mutated ovarian cancer, with rucaparib-treated patients having a confirmed objective response rate of 54%. Furthermore, as demonstrated in the randomized, placebo-controlled, phase III ARIEL3 trial, rucaparib significantly improved progression-free survival when used as maintenance treatment in patients with platinum-sensitive ovarian cancer. Rucaparib had an acceptable tolerability profile in clinical trials in women with ovarian cancer. Common adverse events were generally manageable with dose modification and/or supportive care. Thus, currently available data indicate that rucaparib is a useful addition to the options available to clinicians for the treatment of advanced ovarian cancer, in both the treatment and maintenance therapy settings.


Read abstract on library site Access full article